ABSTRACT
The dramatic increase of obesity worldwide is the driving force behind the pandemic of the metabolic syndrome, type 2 diabetes, and consequently for the new rise of cardiovascular disease (CVD) morbidity and mortality. Obesity is in most, but not all, subjects associated with excessive visceral fat that clusters with vascular risk factors. A close interaction between visceral obesity, non-alcoholic fatty liver disease (NAFLD), and dyslipidemia have been well documented (1-3). The unique anatomical relation of visceral fat to the hepatic portal circulation and consequently to hepatic lipoprotein metabolism has led to intensive endeavor to unravel the pathophysiology and the initiating factors for dyslipidemia.
